Blogs

Celgene @ASCO 2017

Posted by Nirmala Vittaladevuni on May 31, 2017

0
Category: ASCO17, Oncology
Tags: ,
Celgene will demonstrate its broad range of Oncology Clinical Development Program evaluating its investigational pipeline & marketed products at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative research. In multiple myeloma, abstracts will continue to support the role of Celgene’s IMiD® therapies as the foundation of multiple myeloma research, including in the
The remote patient management or tele-healthcare as a concept is only starting to take off in Oncology. The readouts, though limited by their small sample size, have shown positive impact of technology on care providers, patient outcomes and the overall cost burden. Normally, larger studies would be needed to validate these observations. It is unclear if such large scale publicly funded studies will be undertaken. It is more likely that market competition will drive individual

BMS @ASCO 2017

Posted by Nirmala Vittaladevuni on May 30, 2017

0
Category: ASCO17, Oncology
Tags: ,
Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 More than 80 presentations (including16 oral presentations and 7 poster discussions), highlighting data from Company-sponsored studies, collaborations and IS research spanning 20 types of cancer, with focus on research of precision therapies aimed at improving standards of care. The presentations represent the breadth of the Company’s Oncology research portfolio, including monotherapy and combination studies of Opdivo and

AstraZeneca @ASCO 2017

Posted by Nirmala Vittaladevuni on May 30, 2017

0
Category: ASCO17, Oncology
AstraZeneca (AZ), along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, 2-6 June 2017. With three new oncology medicines addressing the unmet needs of patients with ovarian, lung, and bladder cancers approved in under three years, AZ is now halfway to delivering on

Amgen @ASCO 2017

Posted by Nirmala Vittaladevuni on May 30, 2017

0
Category: ASCO17, Oncology
Tags: ,
Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease. XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO® First Randomized Study to

AbbVie @ASCO 2017

Posted by Nirmala Vittaladevuni on May 30, 2017

0
Category: ASCO17, Oncology
Tags: ,
AbbVie will present a total of 23 abstracts across several tumor types including brain cancer, hematologic malignancies, breast cancer, lung cancer and other solid tumors. Researchers will present efficacy and safety data on depatuxizumab mafodotin, an antibody-drug conjugate (ADC) being studied for the treatment of adults with amplified EGFR newly diagnosed or recurrent GBM. The most common genetic alteration in GBM, EGFR-amplification, occurs in approximately 50 percent of GBM patients. Additional presentation include data from